Insmed Incorporated (INSM)
INSM Stock Price Chart
Explore Insmed Incorporated interactive price chart. Choose custom timeframes to analyze INSM price movements and trends.
INSM Company Profile
Discover essential business fundamentals and corporate details for Insmed Incorporated (INSM) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Pharmaceuticals
IPO Date
1 Jun 2000
Employees
1.27K
Website
https://www.insmed.comCEO
William H. Lewis
Description
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.
INSM Financial Timeline
Browse a chronological timeline of Insmed Incorporated corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 May 2026
Upcoming earnings on 18 Feb 2026
Upcoming earnings on 30 Oct 2025
EPS estimate is -$1.35, while revenue estimate is $113.89M.
Earnings released on 7 Aug 2025
EPS came in at -$1.70 falling short of the estimated -$1.29 by -31.78%, while revenue for the quarter reached $107.42M , beating expectations by +3.16%.
Earnings released on 8 May 2025
EPS came in at -$1.42 falling short of the estimated -$1.34 by -5.97%, while revenue for the quarter reached $92.82M , beating expectations by +1.48%.
Earnings released on 20 Feb 2025
EPS came in at -$1.32 falling short of the estimated -$1.17 by -12.82%, while revenue for the quarter reached $104.44M , beating expectations by +2.31%.
Earnings released on 31 Oct 2024
EPS came in at -$1.27 falling short of the estimated -$1.20 by -5.83%, while revenue for the quarter reached $93.43M , beating expectations by +0.07%.
Earnings released on 8 Aug 2024
EPS came in at -$1.94 falling short of the estimated -$1.24 by -56.45%, while revenue for the quarter reached $90.34M , beating expectations by +2.71%.
Earnings released on 9 May 2024
EPS came in at -$1.06 surpassing the estimated -$1.24 by +14.52%, while revenue for the quarter reached $75.50M , missing expectations by -2.90%.
Earnings released on 22 Feb 2024
EPS came in at -$1.28 falling short of the estimated -$1.13 by -13.27%, while revenue for the quarter reached $83.69M , beating expectations by +1.58%.
Earnings released on 26 Oct 2023
EPS came in at -$1.10 falling short of the estimated -$1.06 by -3.77%, while revenue for the quarter reached $79.07M , missing expectations by -0.07%.
Earnings released on 3 Aug 2023
EPS came in at -$1.78 falling short of the estimated -$1.10 by -61.82%, while revenue for the quarter reached $77.23M , beating expectations by +9.98%.
Earnings released on 4 May 2023
EPS came in at -$1.17 falling short of the estimated -$1.08 by -8.33%, while revenue for the quarter reached $65.21M , beating expectations by +1.09%.
Earnings released on 23 Feb 2023
EPS came in at -$1.20 falling short of the estimated -$1.00 by -20.00%, while revenue for the quarter reached $59.30M , missing expectations by -4.49%.
Earnings released on 27 Oct 2022
EPS came in at -$1.09 falling short of the estimated -$0.89 by -22.47%, while revenue for the quarter reached $67.73M , beating expectations by +1.31%.
Earnings released on 4 Aug 2022
EPS came in at -$0.80 surpassing the estimated -$0.89 by +10.11%, while revenue for the quarter reached $65.22M , beating expectations by +10.93%.
Earnings released on 5 May 2022
EPS came in at -$0.80 surpassing the estimated -$0.91 by +12.09%, while revenue for the quarter reached $53.11M , missing expectations by -0.32%.
Earnings released on 17 Feb 2022
EPS came in at -$0.95 falling short of the estimated -$0.89 by -6.74%, while revenue for the quarter reached $56.12M , beating expectations by +11.47%.
Earnings released on 28 Oct 2021
EPS came in at -$0.96 falling short of the estimated -$0.83 by -15.66%, while revenue for the quarter reached $46.76M , missing expectations by -6.88%.
Earnings released on 5 Aug 2021
EPS came in at -$0.94 falling short of the estimated -$0.85 by -10.59%, while revenue for the quarter reached $45.37M , beating expectations by +3.76%.
Earnings released on 6 May 2021
EPS came in at -$0.89 surpassing the estimated -$0.91 by +2.20%, while revenue for the quarter reached $40.21M , missing expectations by -3.42%.
Earnings released on 25 Feb 2021
EPS came in at -$1.00 falling short of the estimated -$0.67 by -49.25%, while revenue for the quarter reached $41.42M , missing expectations by -0.06%.
Earnings released on 29 Oct 2020
EPS came in at -$0.63 falling short of the estimated -$0.59 by -6.78%, while revenue for the quarter reached $43.64M , beating expectations by +3.28%.
INSM Stock Performance
Access detailed INSM performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.